Anaesthetic surplus

Anyone planning an operation tends to focus primarily on the procedure itself, but the post-operative period carries its own risks. Anaesthetic carry-over is one of the well-known complications in anaesthesiology and particularly affects older patients or those with impaired liver or kidney function. Receiving thorough information before the procedure helps to avoid unpleasant surprises in the recovery room.

What is an anaesthetic surplus?

• Persistent anaesthetic effect following completion of the procedure
• Occurs when the rate of elimination does not reduce the drug concentration quickly enough
• Clinically manifests as delayed waking, breathing difficulties or residual muscle weakness
• Is detected and treated in the recovery room through close monitoring

Anaesthetic surplus is a post-operative complication in which anaesthetics or their metabolites remain active in the body even though the surgical procedure has already been completed. The term describes the state between the end of anaesthetic administration and the patient’s full recovery. In technical terms, anaesthetic carry-over is a form of drug carry-over that occurs specifically in the context of anaesthesiology.

Clinically, anaesthetic carry-over manifests as a spectrum ranging from mild drowsiness to respiratory depression requiring treatment. According to the ICD-10 classification system, an adverse effect of anaesthetics is recorded under T88.5. The severity depends on the substance used, the dosage and the individual patient’s characteristics.

Anaesthetic surplus vs. drug surplus: the key distinction

Drug carry-over is the overarching pharmacological term for the persistence of the effect of any medicinal product beyond the therapeutically desired period. Anaesthetic residual effect refers to the drug residual effect exclusively in the context of anaesthesia, i.e. the delayed dissipation of general anaesthetics, muscle relaxants, opioids or sedatives following a surgical procedure.

Any residual anaesthetic effect is therefore a subtype of residual drug effect, but not every residual drug effect occurs following anaesthesia. A patient who is still tired the next morning after taking a sleeping pill is also experiencing a residual drug effect, but not a residual anaesthetic effect in the clinical sense.

Causes and risk factors of anaesthetic carry-over

• Prolonged plasma half-life due to liver or kidney failure
• Advanced age with reduced metabolic capacity
• Obesity: Accumulation of lipophilic active substances in adipose tissue
• Substances administered in too high a dose or too late
• Interactions between several active substances used simultaneously

Anaesthetic carry-over occurs when the body metabolises the anaesthetic more slowly than the anaesthetist had planned. The decisive factor is the Pharmacokinetics , the totality of the processes that a medicinal product undergoes in the body: absorption, distribution, metabolism and excretion. If any of these processes is slowed down, the level of the active substance remains high for longer than is desirable.

Anaesthetic Overdose: An overview of common classes of substances, patient-related risk factors, typical symptoms and available antagonists for treatment. As at July 2026.

Of particular relevance is the Plasma half-life: the time it takes for the concentration of the active substance in the blood to fall by half. Substances with a long half-life, such as certain benzodiazepines, leave the body much more slowly than short-acting agents such as propofol.

Risk groups: Who is particularly at risk?

Not all patients are at the same risk of anaesthetic carry-over. Anaesthesiology identifies several risk groups for which the anaesthetist must take particular care when adjusting the dosage and choice of anaesthetic agent.

Classes of anaesthetics and their duration of action during post-anaesthesia recovery

• Short-acting substances such as propofol are rapidly eliminated
• Long-acting opioids and benzodiazepines significantly increase the risk of carry-over effects
• Non-depolarising muscle relaxants require active antagonism
• Combined anaesthesia involves the cumulative risks of the individual substances involved

The choice of anaesthetic agents has a direct impact on the risk of post-anaesthesia confusion. An understanding of the main classes of active substances helps to assess the individual risk.

Class of substances	Examples of active ingredients	Typical half-life	Risk of a surplus
Hypnotics / Induction agents	Propofol	short (context-dependent: 1–8 hours)	low for short procedures, higher for long infusions
Inhalation anaesthetics	Sevoflurane, Desflurane	very short (minutes)	low; higher with older techniques (halothane)
Opioids	Fentanyl, remifentanil, sufentanil	Fentanyl: 2–4 hours; remifentanil: 3–10 minutes	medium to high, depending on the substance
Non-depolarising muscle relaxants	Rocuronium, Atracurium, Vecuronium	20–60 mins (clinical effect)	high in the absence of antagonism
Benzodiazepines	Midazolam, Diazepam	Midazolam: 1–4 hours; Diazepam: up to 100 hours	high, particularly in older patients

According to the guidelines of the German Society for Anaesthesiology and Intensive Care Medicine (DGAI), the choice of anaesthetic agent should, as a general rule, be based on the principle of the shortest possible duration of action whilst ensuring a sufficient depth of anaesthesia. Short-acting anaesthetics such as remifentanil or desflurane allow for a faster and more predictable recovery, but do not reduce residual anaesthesia to zero, as individual patient factors always play a role.

Symptoms and monitoring in the recovery room

• Prolonged clouding of consciousness despite the procedure having been completed
• Respiratory depression: reduced respiratory rate and depth of breathing
• Residual muscle weakness: the patient is unable to lift their head or grip firmly
• Hypoxia: a decrease in oxygen saturation, as measured by pulse oximetry
• Circulatory instability in severe cases

Symptoms of post-anaesthetic depression typically become apparent in the recovery room, the specialised monitoring unit where patients are cared for after an operation until their consciousness, breathing and circulation have stabilised. The recovery room (also known as the Post-Anaesthesia Care Unit, PACU) is equipped for continuous monitoring: pulse oximetry, ECG, blood pressure measurement and capnography are standard features.

Recognising clinical signs: from mild to severe

A slight residual anaesthetic effect is often manifested only by drowsiness, a slowed response to verbal stimuli or mild disorientation. The patient is breathing spontaneously, and oxygen saturation remains within the normal range. Nursing staff record the Alderete score or the modified Alderete score in order to objectively assess whether the patient is ready for discharge from the recovery room.

Significant residual anaesthesia is indicated by respiratory depression, recognisable by a respiratory rate of less than 10 breaths per minute and a falling oxygen saturation below 94 %. Residual muscle weakness due to excess muscle relaxant can be assessed using the bedside test: if the patient can lift their head off the pillow for five seconds, neuromuscular function has been sufficiently restored. If they cannot, there is an excess of muscle relaxant that requires treatment.

Hypoxia resulting from anaesthetic carry-over is clinically significant: if oxygen saturation falls below 90 %, immediate intervention is required. The nursing staff in the recovery room are specially trained to deal with this.

Treatment: Antagonisation and targeted monitoring

The management of anaesthetic excess depends on the class of substance responsible. If the excess is caused by non-depolarising muscle relaxants, the Antagonisation, also known as decurarisation, is a targeted reversal of the residual effects. Sugammadex is the more modern and selective active substance: it binds directly to rocuronium and vecuronium and reverses their effects within a few minutes. Neostigmine, by contrast, inhibits the breakdown of acetylcholine at the motor end-plate, but is less selective.

In cases of opioid overdose, naloxone is used; this is a pure opioid antagonist that rapidly reverses respiratory depression. Naloxone is administered in titrated doses, i.e. in small increments, to avoid an abrupt pain reaction in the patient. As naloxone has a shorter duration of action than some opioids, repeated administration may be necessary in the case of long-acting substances.

Benzodiazepine residual effects can be antagonised with flumazenil. Important: Flumazenil has a shorter half-life than most benzodiazepines. Patients who have been given flumazenil must therefore be monitored for longer in the recovery room, as sedation may return once the effects of the antagonist have worn off.

Prevention: specifically avoiding excess anaesthesia

The most effective protection against anaesthetic over-exposure is pre-operative risk assessment. Before each procedure, the anaesthetist takes a full medical and medication history, checks liver and kidney function tests, and selects anaesthetic agents in accordance with the patient’s individual risk profile. In high-risk patients, such as those with severe obesity or advanced age, short-acting agents are preferred, the dosage is carefully calculated, and neuromuscular monitoring is used throughout the entire operation.

Neuromuscular monitoring using the Train-of-Four (TOF) stimulus is particularly helpful in this regard: four electrical stimuli applied to the nerve indicate the extent to which neuromuscular blockade has been resolved. According to the professional association, a TOF ratio of at least 0.9 is considered safe for extubation. Without this monitoring, residual neuromuscular blockade often goes clinically unnoticed.

Excess anaesthetic use in cosmetic surgery: what you need to know

• Even with cosmetic procedures carried out under general anaesthesia, there is a risk of anaesthetic carry-over
• Pre-procedure counselling should take individual risk factors into account
• Choose a clinic with its own recovery room and specialist anaesthesia staff
• Complications arising in connection with anaesthesia may result in additional costs

Cosmetic surgery, ranging from liposuction to eyelid lifts, is usually carried out under general anaesthesia or deep sedation. The same anaesthesiological principles therefore apply as for other operations: the risk of residual anaesthetic effects depends on the substances used, the duration of the operation and the patient’s individual risk profile.

Typical risk factors that should be given particular consideration prior to cosmetic surgery include being overweight, taking certain medication (such as psychotropic drugs or anticoagulants) and abnormal liver function test results. Experience has shown that longer procedures in particular – such as combination operations lasting several hours – lead to an increased risk of accumulation when several substances are administered simultaneously.

Not every clinic that offers cosmetic procedures has a fully equipped recovery room with anaesthesia specialists on duty at all times. Before your procedure, ask specifically how post-operative monitoring is organised and what emergency measures are in place in the event of prolonged anaesthesia.

Note on financial protection: Complications following cosmetic surgery, including those arising from the anaesthesia, may require follow-up treatment which is not covered by statutory health insurance. A Consequential Costs Insurance covers precisely these costs, without patients having to bear the financial burden themselves. Information on Finance a treatment You can also find this on our website.

Frequently asked questions about anaesthetic surplus